Online citations, reference lists, and bibliographies.
← Back to Search

Randomized Phase III Trial Comparing Single-Agent Paclitaxel Poliglumex (CT-2103, PPX) With Single-Agent Gemcitabine Or Vinorelbine For The Treatment Of PS 2 Patients With Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer

M. O'brien, M. Socinski, A. Y. Popovich, I. Bondarenko, A. Tomova, Borys T. Bilynsky˘ı, Y. Hotko, V. L. Ganul, Ippolit Y Kostinsky, A. Eisenfeld, L. Sandalic, F. Oldham, B. Bandstra, A. Sandler, J. Singer
Published 2008 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Background: Patients with advanced non-small cell lung cancer (NSCLC) and impaired performance status (PS ≥ 2) have limited life expectancies and decreased tolerance for drug-induced toxicities. Current treatment guidelines indicate that PS 2 patients benefit from systemic therapy. Further refinement of treatment in these patients requires reduction of treatment-associated toxicities while maintaining or improving efficacy. Paclitaxel poliglumex (PPX), a macromolecular polymer–drug conjugate of paclitaxel and poly-l-glutamic acid, may enhance the therapeutic index of paclitaxel. Methods: Chemotherapy-naive PS 2 patients with advanced NSCLC randomly received single-agent PPX (175 mg/m2) or a comparator (single-agent vinorelbine or gemcitabine). The primary end point of this study was overall survival. Results: Overall survival was similar between treatment arms (hazard ratio [HR] = 0.95; log-rank p = 0.686). Median and 1-year survival were 7.3 months and 26%, respectively, for PPX versus 6.6 months and 26% for the control arm. There was a nonsignificant trend toward improved survival in women in the PPX arm compared with standard single agents (HR = 0.65; p = 0.069). The most frequent grade 3/4 adverse events in the treatment versus control arm were dyspnea (13% versus 17%, respectively) and fatigue (10% versus 9%). Grade 3/4 neutropenia and anemia were reduced in the PPX arm (2% versus 8% and 3% versus 9%, respectively). Neuropathy, a taxane-specific toxicity, was more common in the PPX arm; grade 3 neuropathy was limited to 3%. Conclusions: Single-agent PPX, dosed at 175 mg/m2, is active and well tolerated in PS 2 patients with advanced NSCLC. Patients on PPX required fewer red blood cell transfusions, hematopoietic growth factors, opioid analgesics, and clinic visits than patients receiving gemcitabine or vinorelbine.
This paper references
XYOTAX (paclitaxel poliglumex, PPX): tumor accumulation and prolonged exposure to paclitaxel
A Bernareggi
10.1093/jnci/92.3.205
New Guidelines to Evaluate the Response to Treatment in Solid Tumors.
P. Therasse (2000)
10.1634/THEONCOLOGIST.9-4-398
Dilemmas in management: the controversial role of chemotherapy in PS 2 advanced NSCLC and the potential role of CT-2103 (Xyotax).
C. Langer (2004)
10.3322/canjclin.39.6.399
Cancer statistics
N. Dubrawsky (1989)
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.
P. Therasse (2000)
10.1200/jco.2004.22.14_suppl.7058
Gemcitabine (G) vs gemcitabine-carboplatin (GCB) for patients with advanced non-small cell lung cancer (NSCLC) and PS:2. A prospective randomized phase II study of the Hellenic Co-Operative Oncology Group.
P. Kosmidis (2004)
10.3816/CLC.2005.N.004
Results of a phase II trial of gemcitabine in patients with non-small-cell lung cancer and a performance status of 2.
M. Neubauer (2005)
Cigarette smoking among adults--United States, 2002.
C. Husten (2004)
10.1097/01.COT.0000343804.37975.8C
Cigarette Smoking Among Adults in the United States
S. Thorne (2008)
CHEMOTHERAPY FOR ADVANCED NONSMALL CELL LUNG CANCER
R. Herbst (1997)
10.1016/J.JCONREL.2005.09.033
Paclitaxel poliglumex (XYOTAX, CT-2103): a macromolecular taxane.
J. Singer (2005)
10.1023/A:1013574413217
Do all patients with advanced non-small-cell lung cancer benefit from cisplatin-based combination therapy?
J. Soria (2001)
10.1097/01.cco.0000152629.20996.9e
Chemotherapy for advanced non-small cell lung cancer patients with performance status 2
F. Blackhall (2005)
10.1002/SIM.1897
Design and analysis of non-inferiority mortality trials in oncology.
K. Carroll (2004)
XYOTAX (paclitaxel poliglumex, PPX): tumor accumulation and prolonged exposure to paclitaxel [abstract
A Bernareggi (2005)
10.3322/canjclin.55.1.10
Cancer Statistics, 2005
A. Jemal (2005)
10.1016/S0169-5002(03)00230-7
The changing epidemiology of lung cancer in Europe.
M. Janssen-Heijnen (2003)
10.1183/2312508x.erm6815
Lung cancer.
H. Hansen (1990)
Results of a phase II trial of gemcitabine in patients with non-small cell lung cancer and a performance status of 2. Clin Lung Cancer 2005;6:245–249
MA Neubauer (2008)
10.1200/JCO.2005.00.224
Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel.
C. Gridelli (2005)
National Cancer Institute: Non-small Cell Lung Cancer (PDQ): Treatment
American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update
DG Pfister (2003)
Update: NCCN small cell and non-small cell lung cancer Clinical Practice Guidelines.
D. Ettinger (2005)
10.1200/JCO.2005.07.172
Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730).
R. Lilenbaum (2005)
10.1200/JCO.2004.04.370
Outcome of patients with a performance status of 2 in the Multicenter Italian Lung Cancer in the Elderly Study (MILES).
F. Perrone (2004)
10.1200/JCO.2004.09.053
American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.
D. Pfister (2004)



This paper is referenced by
10.1007/s00280-009-1099-1
Preclinical efficacy studies of a novel nanoparticle-based formulation of paclitaxel that out-performs Abraxane
Z. Feng (2009)
10.1016/j.jtho.2016.04.025
Progression‐Free Survival, Response Rate, and Disease Control Rate as Predictors of Overall Survival in Phase III Randomized Controlled Trials Evaluating the First‐Line Chemotherapy for Advanced, Locally Advanced, and Recurrent Non–Small Cell Lung Carcinoma
K. Nakashima (2016)
10.4155/9781909453524
Drug Delivery in Oncology
A. Ricart (2014)
Current use of Health-Related Quality of Life Outcomes in Advanced-stage Lung Cancer Clinical Trials
H. Conter (2011)
10.1016/j.bmcl.2008.11.079
N,N-Dimethylsphingosine conjugates of poly-L-glutamic acid: synthesis, characterization, and initial biological evaluation.
Sukhen C. Ghosh (2009)
DESIGN AND SYNTHESIS OF STIMULI-RESPONSIVE POLYMERIC NANOGELS TOWARDS THERAPEUTIC TRANSLATION
Mallory R Gordon (2018)
10.1016/j.addr.2013.10.007
Drug delivery design for intravenous route with integrated physicochemistry, pharmacokinetics and pharmacodynamics: illustration with the case of taxane therapeutics.
L. H. Reddy (2014)
Microtubule-targeted antitumor drugs : chemistry , mechanisms and nanoparticle formulations
T. Boulikas (2009)
10.2217/BMT.13.18
Overview of nanoparticle albumin-bound paclitaxel in metastatic breast cancer
Demetria Ileana Strauch (2013)
10.1021/ab500084g
Nanotherapy for Cancer: Targeting and Multifunctionality in the Future of Cancer Therapies
A. Ediriwickrema (2015)
10.1039/C7PY00169J
Effect of polymer topology on non-covalent polymer–protein complexation: miktoarm versus linear mPEG-poly(glutamic acid) copolymers
A. Nieto-Orellana (2017)
10.1378/chest.12-2361
Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
M. Socinski (2013)
10.1053/j.seminoncol.2009.10.001
Lung cancer outcomes in women.
Danielle Shafer (2009)
10.1016/j.lungcan.2010.12.006
The safety and efficacy of EGFR TKIs monotherapy versus single-agent chemotherapy using third-generation cytotoxics as the first-line treatment for patients with advanced non-small cell lung cancer and poor performance status.
Shan Liu (2011)
10.1016/S0959-8049(11)70171-X
2010 Consensus on Lung Cancer, new clinical recommendations and current status of biomarker assessment--first-line therapy.
Cesare Gridelli (2011)
10.1016/j.cllc.2017.03.005
Assessment of the External Validity of the National Comprehensive Cancer Network and European Society for Medical Oncology Guidelines for Non-Small-Cell Lung Cancer in a Population of Patients Aged 80 Years and Older.
N. M. L. Battisti (2017)
10.1021/bm400615n
Acetal-linked paclitaxel prodrug micellar nanoparticles as a versatile and potent platform for cancer therapy.
Yudan Gu (2013)
10.1111/ajco.12178
Multicenter randomized, open‐label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first‐line therapy in elderly or ECOG PS two patients with advanced NSCLC
M. Michael (2015)
10.1002/POLB.22259
Biomedical Applications of Biodegradable Polymers.
B. Ulery (2011)
10.1016/j.biomaterials.2011.01.073
Integrin-assisted drug delivery of nano-scaled polymer therapeutics bearing paclitaxel.
A. Eldar-Boock (2011)
10.1201/B11620-5
Polyethylene Glycol Polyester Block Copolymers: Biocompatible Carriers for Nanoparticulate Drug Delivery
Dan Peer (2012)
10.1007/978-1-4614-9164-4_7
Polymer-Drug Conjugates
Cristina Fante (2013)
10.4155/fmc.12.217
Tubulin: an example of targeted chemotherapy.
J. Seligmann (2013)
10.5958/2231-5713.2015.00008.2
A Review- Emerging Use of Nano-Based Carriers in Diagnosis and Treatment of Cancer-Novel Approaches
Yaqub Khan (2015)
10.3816/CLC.2008.n.047
New treatment strategies in patients with advanced non-small-cell lung cancer and performance status 2.
E. Rodriguez (2008)
10.1021/acs.chemrev.5b00116
Clinical Translation of Nanomedicine.
Y. Min (2015)
10.2745/DDS.24.28
Clinical trials of NK105, a paclitaxel incorporating micellar nanoparticle formation
Ken Kato (2009)
10.3390/cancers3010017
Clinically Relevant Anticancer Polymer Paclitaxel Therapeutics
Danbo Yang (2010)
10.1166/JBN.2015.2145
Recent Developments in Active Tumor Targeted Multifunctional Nanoparticles for Combination Chemotherapy in Cancer Treatment and Imaging.
M. Glasgow (2015)
10.1038/sj.bjc.6604372
Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer
L. Paz-Ares (2008)
10.1002/wnan.1497
A hindsight reflection on the clinical studies of poly(l-glutamic acid)-paclitaxel.
Jun Zhao (2018)
10.1016/j.critrevonc.2012.09.009
Optimizing taxane use in MBC in the emerging era of targeted chemotherapy.
G. von Minckwitz (2013)
See more
Semantic Scholar Logo Some data provided by SemanticScholar